4-Hexylresorcinol Bone Therapy for Osteoclast-Sparing Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional bisphosphonate-based drugs for treating bone diseases like osteoporosis have side effects such as osteoclast death, osteonecrosis of jaws, atypical fracture, delayed fracture healing, and injection discomfort, necessitating the development of a therapeutic agent that inhibits osteoclast activity without inducing cell death and stimulates osteoblast activity, while being easy to administer.
Innovation Solution
A pharmaceutical composition comprising 4-hexylresorcinol (4-HR) or a pharmaceutically acceptable salt as an active ingredient, formulated as an ointment, which promotes osteoblast differentiation and suppresses osteoclast proliferation and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bisphosphonate-based drugs are used to treat bone diseases, then osteoclast activity is inhibited and bone resorption is reduced, but side effects occur including osteoclast death, osteonecrosis of jaws, atypical fracture, delayed fracture healing, and injection discomfort
Solution Approach 1:
The patent extracts and eliminates the harmful side effects of conventional bisphosphonate-based drugs while retaining the beneficial osteoclast inhibition effect. By developing a novel compound that selectively inhibits osteoclast activity without causing cell death or other adverse effects, the invention separates the therapeutic action from the harmful consequences.
Solution Approach 2:
The patent changes the chemical and pharmacological parameters of the treatment by introducing a new compound with modified properties. This novel compound achieves osteoclast inhibition through a different mechanism that avoids the toxic effects associated with bisphosphonates, thereby altering the safety profile while maintaining efficacy.
2Object-affected harmful factors
If therapeutic agents are developed to inhibit osteoclast activity without inducing cell death, then safety is improved, but the complexity of drug development increases
Solution Approach 1:
The patent introduces a novel compound as an intermediary substance that mediates the inhibition of osteoclast activity without triggering cell death. This intermediary agent provides a safer mechanism of action compared to conventional drugs, achieving the desired therapeutic effect through a different biochemical pathway.
3Strength
If a therapeutic agent stimulates osteoblast activity and improves bone formation, then bone density and strength increase, but the risk of inducing abnormal bone growth or other unintended effects may increase
Solution Approach 1:
The patent applies local quality by targeting specific bone tissue regions and cell types with the novel compound. The drug exhibits selective action on osteoblasts and osteoclasts at specific sites, promoting bone formation where needed while avoiding abnormal growth in other areas through localized and controlled pharmacological effects.
Data Source
AI summary
The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.